TRANSFORM and ZUMA-7: A Discussion on Efficacy and Safety of CAR T in R/R DLBCL

Opinion
Video

Panelists discuss the efficacy and safety of chimeric antigen receptor T-cell (CAR T) therapy in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) and compare the data collected from the TRANSFORM and ZUMA-7 trials, including information regarding the patient control group, patient population prior response, crossovers of both trials, and vein-to-vein time.

Recent Videos
5 experts in this video
6 experts are featured in this series.
6 experts are featured in this series.
5 experts in this video
Related Content